KIRIN HOLDINGS CO-SPON ADR Business Summary

Kirin Holdings Company, Limited (KNBWY) operates a diversified global business model centered on the "Creating Shared Value" (CSV) framework, generating revenue through the manufacturing and distribution of alcoholic beverages, soft drinks, pharmaceuticals, and health science products. The company’s primary business segments include Japan Beer and Spirits, Japan Non-Alcoholic Beverages, Oceania Integrated Beverages (via Lion), Pharmaceuticals (through its majority stake in Kyowa Kirin), and a rapidly expanding Health Science domain bolstered by the acquisitions of Blackmores and Fancl. Kirin leverages its core expertise in fermentation and biotechnology to transition from a traditional brewery into a high-margin life sciences conglomerate, recently divesting its Four Roses distillery assets in early 2026 to sharpen its strategic focus. In the competitive landscape, Kirin maintains a dominant position as Japan's second-largest brewer, trailing Asahi Group Holdings but competing aggressively with Suntory Holdings, Sapporo Holdings, and global giants like Anheuser-Busch InBev. Its strategic differentiation lies in its unique integration of pharmaceutical R&D with consumer health products, a pivot designed to offset declining domestic alcohol consumption. The company’s leadership is currently anchored by Representative Director and CEO Yoshinori Isozaki, who has overseen Kirin’s transformation into a diversified health-focused group, and Representative Director, President, and COO Takeshi Minakata, an industry veteran with extensive experience in Kirin’s international and planning divisions. Key leadership in the high-growth pharmaceutical segment includes Abdul Mullick, who became the first non-Japanese CEO of Kyowa Kirin in March 2026, while Alastair Symington leads the international health science business following the Blackmores integration. The board is supported by notable independent directors such as Hiroyuki Yanagi and Shinya Katanozaka, ensuring robust corporate governance under the "Innovate2035!" long-term vision. Major institutional shareholders include The Master Trust Bank of Japan and the Custody Bank of Japan, reflecting its status as a core component of the Nikkei 225. The KNBWY ADR provides U.S. investors with direct exposure to this evolving portfolio of beverage and biotechnology assets.